# The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease

> **NCT01181921** · PHASE4 · TERMINATED · sponsor: **Janssen-Cilag, S.A.** · enrollment: 1 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Galantamine

## Key facts

- **NCT ID:** NCT01181921
- **Lead sponsor:** Janssen-Cilag, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The recruitment rate was very low (one screening failure and one early withdrawal patient)
- **Last updated:** 2014-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01181921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01181921, "The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01181921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*